Detalhe da pesquisa
1.
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer.
Br J Cancer;
130(6): 941-950, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38245661
2.
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial.
Int J Gynecol Cancer;
2024 May 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38724236
3.
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Gynecol Oncol;
172: 121-129, 2023 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37030280
4.
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
Int J Gynecol Cancer;
33(8): 1253-1259, 2023 08 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37072323
5.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol;
23(7): 919-930, 2022 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35690073
6.
The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
Br J Cancer;
126(6): 851-864, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34716396
7.
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours.
Br J Cancer;
127(1): 92-101, 2022 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35568736
8.
BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
Br J Cancer;
127(1): 163-167, 2022 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35260807
9.
c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial.
BMC Med;
20(1): 59, 2022 02 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35144591
10.
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
Gynecol Oncol;
165(1): 40-48, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35115180
11.
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Gynecol Oncol;
167(3): 404-413, 2022 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36273926
12.
Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.
Cochrane Database Syst Rev;
2: CD012007, 2022 Feb 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35188221
13.
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Lancet Oncol;
22(2): 277-288, 2021 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33357510
14.
Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study.
BMC Cancer;
21(1): 378, 2021 Apr 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33832445
15.
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
Gynecol Oncol;
163(1): 72-78, 2021 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34412908
16.
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
Int J Gynecol Cancer;
31(7): 949-958, 2021 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34103386
17.
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.
Lancet Oncol;
21(7): 969-977, 2020 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32615110
18.
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Lancet Oncol;
21(5): 710-722, 2020 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32359490
19.
Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
Br J Cancer;
122(4): 483-490, 2020 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31813938
20.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Lancet;
394(10214): 2084-2095, 2019 12 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31791688